Verosudil Hydrochloride | 1414854-44-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Verosudil Hydrochloride
• 英文别名: 2-(dimethylamino)-N-(1-oxo-2H-isoquinolin-6-yl)-2-thiophen-3-ylacetamide;hydrochloride
• CAS: 1414854-44-6
• 化学式: C17H18ClN3O2S
• 分子量: 363.9
• InChiKey: FUBBJNODZIIYHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.25
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  89.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  以96的产率得到Verosudil Hydrochloride
  参考文献：
  名称：

  6-and 7-amino isoquinoline compounds and methods for making and using the same

  摘要：

  提供了6-和7-氨基异喹啉化合物，可以影响、抑制或减少激酶的作用。还提供了包含治疗有效量的6-和7-氨基异喹啉化合物和药用可接受载体的制药组合物。还提供了使用这些化合物和/或组合物来影响疾病状态或状况，如癌症、肥胖和青光眼的各种方法。

  公开号：

  US08871757B2

文献信息

• [EN] COMBINATION THERAPY<br/>[FR] TRAITEMENT COMBINÉ
  申请人：AERIE PHARMACEUTICALS INC

  公开号：WO2014144781A1

  公开（公告）日：2014-09-18

  Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

  本文描述了用于治疗青光眼和/或降低眼压的化合物和组合物。组合物可能包括异喹啉化合物和一种前列腺素或前列腺素类似物。本文描述的化合物包括异喹啉化合物与前列腺素或前列腺素类似物共价连接的化合物，以及异喹啉化合物和前列腺素游离酸一起形成盐的化合物。
• 6-And 7-amino isoquinoline compounds and methods for making and using the same
  申请人：deLong Mitchell A.

  公开号：US20090186917A1

  公开（公告）日：2009-07-23

  6- and 7-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6- and 7-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  提供了影响、抑制或减少激酶作用的6-和7-氨基异喹啉化合物。还提供了包括治疗有效量的6-和7-氨基异喹啉化合物和药用可接受载体的制药组合物。还提供了使用这些化合物和/或组合物来影响疾病状态或疾病条件，如癌症、肥胖和青光眼的各种方法。
• 6-and 7-amino isoquinoline compounds and methods for making and using the same
  申请人：deLong Mitchell A.

  公开号：US08871757B2

  公开（公告）日：2014-10-28

  6- and 7-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6- and 7-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  提供了6-和7-氨基异喹啉化合物，可以影响、抑制或减少激酶的作用。还提供了包含治疗有效量的6-和7-氨基异喹啉化合物和药用可接受载体的制药组合物。还提供了使用这些化合物和/或组合物来影响疾病状态或状况，如癌症、肥胖和青光眼的各种方法。
• 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME
  申请人：deLong Mitchell A.

  公开号：US20100144713A1

  公开（公告）日：2010-06-10

  6- and 7-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6- and 7-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  提供了影响、抑制或减少激酶作用的6-和7-氨基异喹啉化合物。还提供了包括治疗有效量的6-和7-氨基异喹啉化合物和药学上可接受的载体的制药组合物。还提供了使用这些化合物和/或组合物影响癌症、肥胖症和青光眼等疾病状态或病症的各种方法。
• COMBINATION THERAPY
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US20160243105A1

  公开（公告）日：2016-08-25

  Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

  本文描述了用于治疗青光眼和/或降低眼内压力的化合物和组合物。组合物可以包括异喹啉化合物和前列腺素或前列腺素类似物。所描述的化合物包括那些异喹啉化合物与前列腺素或前列腺素类似物共价键结合的化合物，以及异喹啉化合物和前列腺素自由酸一起形成盐的化合物。